Procedure
Deep Brain Stimulation for Opioid Addiction
This trial is testing a device that sends electrical signals to the brain to help people with severe opioid addiction who haven't been helped by other treatments. The device aims to control brain areas involved in addiction and behavior. Current experimental evidence indicates that this method has excellent potential to help with treatment, showing fewer side effects and better adherence.
Behavioral Intervention
Harm Reduction Kiosk for Substance Use-Related Health Risks
This trial will test a new harm reduction kiosk called KyOSK in rural Appalachia to help people who use drugs stay safer. The kiosk provides clean needles and other supplies to reduce the risk of HIV, hepatitis C, and overdoses. The study aims to determine if this new approach is more effective and cost-efficient.
Popular Filters
Trials for Opioid Use Disorder Patients
Behavioural Intervention
Smartphone Apps for Opioid Use Disorder
This trial would use apps to help prevent relapse among patients receiving treatment for opioid use disorder. The apps would track the person's location and offer targeted, personalized intervention when they enter an area at high risk for relapse.
Behavioural Intervention
CBD for Opioid Use Disorder
This trial will test if CBD can help reduce craving and anxiety in people abstaining from heroin. Brain scans will be taken before and after CBD administration to see how it affects neural circuits and transmitters.
Learning Health System Intervention for Substance Use Disorders
This trial seeks to address the national addiction crisis at its epicenter by creating alliances between the juvenile justice system and community mental health centers to disseminate addiction prevention and treatment.
Neuromodulator Medical Device
Bridge Device + Lofexidine for Opioid Use Disorder
This trial is testing a device called the Bridge Device, which uses electrical signals to help people with opioid addiction. The study focuses on individuals who are not currently on any medication for their addiction. The device aims to ease withdrawal symptoms by sending signals to the brain. Participants will be monitored to see if the device effectively reduces withdrawal symptoms.
Trials for OUD Patients
Behavioural Intervention
Smartphone Apps for Opioid Use Disorder
This trial would use apps to help prevent relapse among patients receiving treatment for opioid use disorder. The apps would track the person's location and offer targeted, personalized intervention when they enter an area at high risk for relapse.
Behavioural Intervention
CBD for Opioid Use Disorder
This trial will test if CBD can help reduce craving and anxiety in people abstaining from heroin. Brain scans will be taken before and after CBD administration to see how it affects neural circuits and transmitters.
Learning Health System Intervention for Substance Use Disorders
This trial seeks to address the national addiction crisis at its epicenter by creating alliances between the juvenile justice system and community mental health centers to disseminate addiction prevention and treatment.
Neuromodulator Medical Device
Bridge Device + Lofexidine for Opioid Use Disorder
This trial is testing a device called the Bridge Device, which uses electrical signals to help people with opioid addiction. The study focuses on individuals who are not currently on any medication for their addiction. The device aims to ease withdrawal symptoms by sending signals to the brain. Participants will be monitored to see if the device effectively reduces withdrawal symptoms.
Phase 3 Trials
Neuromodulator Medical Device
Bridge Device + Lofexidine for Opioid Use Disorder
This trial is testing a device called the Bridge Device, which uses electrical signals to help people with opioid addiction. The study focuses on individuals who are not currently on any medication for their addiction. The device aims to ease withdrawal symptoms by sending signals to the brain. Participants will be monitored to see if the device effectively reduces withdrawal symptoms.
Opioid Agonist
Buprenorphine for Opioid Addiction during Pregnancy
This trial is testing whether an extended-release form of buprenorphine is as effective as the standard form in treating pregnant women with opioid use disorder, with the goal of improving outcomes for mother and child.
Opioid Agonist
Extended-release vs Sublingual Buprenorphine for Opioid Use Disorder
This trial will explore how well an extended-release injectable medication helps people with opioid use disorder in rural areas. It will compare it to a standard medication. Results will include patient outcomes.
Trials With No Placebo
Behavioural Intervention
Smartphone Apps for Opioid Use Disorder
This trial would use apps to help prevent relapse among patients receiving treatment for opioid use disorder. The apps would track the person's location and offer targeted, personalized intervention when they enter an area at high risk for relapse.
Learning Health System Intervention for Substance Use Disorders
This trial seeks to address the national addiction crisis at its epicenter by creating alliances between the juvenile justice system and community mental health centers to disseminate addiction prevention and treatment.
Opioid Agonist
Buprenorphine for Opioid Addiction during Pregnancy
This trial is testing whether an extended-release form of buprenorphine is as effective as the standard form in treating pregnant women with opioid use disorder, with the goal of improving outcomes for mother and child.
View More Related Trials
Frequently Asked Questions
Introduction to opiate addiction
What are the top hospitals conducting opiate addiction research?
In the battle against opiate addiction, top hospitals across the United States are tirelessly working to develop effective treatments and interventions. One such institution is Boston Medical Center in Boston, which currently has six active clinical trials focused on opiate addiction. With a total of 11 trials conducted thus far, their commitment to tackling this crisis was evident from their inaugural trial in 2009. Another notable player in this field is the University of Kentucky located in Lexington, with five ongoing opiate addiction trials and a solid track record of nine completed studies since their first trial back in 2006.
Notably joining these renowned hospitals is Gateway Community Services based in Jacksonville. Despite having a smaller number of three active opiate addiction trials and four completed studies to its name, Gateway Community Services made significant strides by embarking on its first recorded opiate addiction trial as recent as 2020—a testament to their dedication towards combating this pressing issue.
Closer to home for some patients can be found at Massachusetts General Hospital HOPE Clinic situated within Boston itself; it shares similar progress with three current open clinical tests along-side three prior endeavors that all began further fueling research during the year2020.
Lastly but not least important among these leading institutions stands out Pregnancy Recovery Center at Magee-Womens Hospital of UPMC positioned firmly within Pittsburgh's healthcare landscape specializing primarily catered towards women facing opioid dependency issues; actively participating through conducting three different active investigations while completing another two previously initiated ones- each forming part integral contribution during past year itself displaying unwavering commitment providing aid & solutions needed for afflicted individuals
These remarkable hospitals symbolize hope for those grappling with opiate addiction by ensuring that innovative approaches are explored continuously. As they strive forward collectively underlining an urgent need encompassing diverse regions throughout America-it becomes clearer than ever before: The fight against opioid abuse demands our united resilience coupled together progressively forging ahead until every roadblock ceases existence
Which are the best cities for opiate addiction clinical trials?
When it comes to opiate addiction clinical trials, several cities emerge as prominent locations for research and treatment. Boston, Massachusetts takes the lead with 16 active trials investigating interventions like Buprenorphine Injection, Psilocybin, and Communities That HEAL. Following closely behind is Albuquerque, New mexico with 10 ongoing studies focusing on approaches such as Collaborative care Plus and Substance Use Treatment and Recovery Team (START). New york City also has 10 active trials exploring treatments including Pharmacogenetic testing and Cannabidiol (CBD). Additionally, Lexington in Kentucky and Atlanta in Georgia both have 7 active trials each that examine various interventions for opiate addiction. These cities offer individuals battling this epidemic an opportunity to participate in cutting-edge clinical research aimed at finding better solutions for recovery.
Which are the top treatments for opiate addiction being explored in clinical trials?
Clinical trials are actively exploring various treatments for opiate addiction, with Buprenorphine Injection emerging as one of the top contenders. This powerful medication is currently being tested in three active trials dedicated to combatting opiate addiction. Since its first listing in 2020, it has gained attention and involvement in a total of three all-time clinical trials focused on addressing this pressing issue. As researchers delve deeper into finding effective solutions, the potential impact of Buprenorphine Injection offers hope for individuals battling opiate addiction.
What are the most recent clinical trials for opiate addiction?
Exciting developments are underway in the field of opiate addiction treatment, with recent clinical trials offering promising options for individuals seeking recovery. Among these trials is continuous intercostal nerve block (CINB), a Phase 4 study that explores its effectiveness in managing opiate addiction. Additionally, Aurora 1:1 Drops (Indica) and Liposomal Bupivacaine have shown potential benefits as interventions for opiate addiction in Phase 2 and Phase 3 trials respectively. Another important trial investigates the use of a transcutaneous cervical vagal nerve stimulation device to address opiate addiction, while ultrasound shear wave elastography examination offers insight into this complex condition through a Phase 4 study. These groundbreaking studies pave the way towards improved solutions for those grappling with opiate addiction, highlighting an encouraging path forward.
What opiate addiction clinical trials were recently completed?
The field of opiate addiction has seen several recent clinical trials reaching completion, offering new insights and potential treatments for this pressing issue. In August 2022, Indivior Inc.'s trial on INDV-2000 concluded successfully, followed closely by BioCorRx Pharmaceuticals, Inc.'s BICX104 trial in June 2022. Notably, Go Medical Industries Pty Ltd completed their Naltrexone 380 MG study in January 2021. Among earlier accomplishments is the December 2020 completion of a Ketamine Hydrochloride trial led by the Medical University of South carolina and an Emory University-led Non invasive VN stimulation (nVNS) trial in November 2020. NYU Langone Health's Buprenorphine Naloxone study also concluded that same month. While Jacques E. Chelly's Ketamine trial wrapped up in December 2019 and Alar Pharmaceuticals Inc.'s ALA-1000 study reached its end point in September of that year.